Advanced Filters
noise

Broomall, Pennsylvania Clinical Trials

A listing of Broomall, Pennsylvania clinical trials actively recruiting patient volunteers.

Found 850 clinical trials
E Erin K Schubert

Multi-System Analysis of Opioid Receptor Binding

This study will enroll up to 60 adults (including 30 females and 30 males) in three cohorts of up to 20 subjects each. In all three groups, [11C]carfentanil whole-body PET imaging will be used to examine the central nervous system (CNS) and broader systemic opioid binding in an initial scan …

18 - 50 years of age All Phase 1
L Lauren Mitteer

A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)

The main goal of this trial is to evaluate the safety and tolerability of mRNA-3745 via intravenous (IV) administration in adult and pediatric participants with GSD1a.

6 years of age All Phase 1/2
L Lisa Joseph

JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization

Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints. Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years …

21 years of age All Phase N/A
C Cancer Connect

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have a genetic abnormality called BRAFV600E mutation and is not associated with systemic neurofibromatosis type …

2 - 21 years of age All Phase 3
C Carmen Cook, RN

Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis

This is a multicenter, international, three-part, Phase 1 study designed to evaluate the safety, tolerability, and PK of rising single doses of AT-02 in healthy volunteers and in subjects with systemic amyloidosis and to assess the safety, tolerability, and PK of multiple doses of AT-02 in subjects with systemic amyloidosis.

18 years of age All Phase 1
L Lisa Borodyanskaya

Mobility and Voiding Exercises in Older Women With Urinary Incontinence (MoVEonUp)

A prospective, two-arm randomized clinical trial utilizing a multidimensional intervention to reduce falls in older women with Urinary Urge Incontinence. The intervention consist of general balance and strength training, bladder training and urge suppression, and home hazard assessments. The control group will receive informational booklets on fall prevention and behavioral …

70 years of age Female Phase N/A
D Donald S Malay, DPM

Plantar Fasciitis Randomized Clinical Control Trial

The primary aim of this clinical experiment is to compare, in terms of pain relief measured using the 10-cm visual analog scale (VAS) pain score (5-7), the clinical results of ultrasound-guided injection (USGI) versus anatomic topography-guided injection (ATGI) of corticosteroid for the treatment of proximal PF. Secondary aims will be …

18 years of age All Phase N/A

Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)

This is a multi-center, double-masked, randomized, placebo-controlled, parallel-group, efficacy, safety, and tolerability study evaluating the efficacy of Dupilumab in the treatment of signs and symptoms of atopic keratoconjunctivitis (AKC).

18 years of age All Phase 2
M Mel V, BA

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.

18 years of age All Phase 1/2
T Thomas White

Phase IB/II of CPX-351 for Relapse Prevention in AML

This is a phase IB/II study with a 3+3 dose de-escalation study design. Patients will continue maintenance treatment with CPX-351 for 6 cycles on D1 and D3, as long as patient remains in CR. The dose de-escalation will be one dose given on D1 only, every 28 days pending toxicity. …

18 years of age All Phase 1/2

Simplify language using AI